Joshua Meeks

13PUBLICATIONS
111CO-AUTHORS
Predictive and prognostic markersInnate immunityNeurology and neuromuscular diseasesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Jan 02, 2026
STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell-induced CD4+ T cell tolerance.

Joseph R Podojil, Andrew C Cogswell, Tobias Neef

|Sep 10, 2025
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.

Lexiaochuan Wen, Hiroko Miyagi, Philippe E Spiess

|Dec 03, 2024
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.

Emanuele Crupi, Tiago Costa de Padua, Laura Marandino

|Jun 06, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Roger Li, Paras H Shah, Tyler F Stewart

|Apr 24, 2024
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz

Pageof 3

Frequent Collaborators

5 joint publications

Ashish M Kamat

4 joint publications

Roger Li

2 joint publications

Oliver Hahn

2 joint publications

Joseph R Podojil